OPKO Health (NASDAQ:OPK) Given Outperform Rating at Barrington Research

OPKO Health (NASDAQ:OPK)‘s stock had its “outperform” rating reissued by investment analysts at Barrington Research in a note issued to investors on Friday, Benzinga reports. They currently have a $2.25 price objective on the biotechnology company’s stock. Barrington Research’s price target points to a potential upside of 52.03% from the company’s current price.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research report on Saturday, July 27th. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Trading Down 6.9 %

Shares of OPK opened at $1.48 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.63 and a quick ratio of 1.36. The firm has a 50 day simple moving average of $1.52 and a 200-day simple moving average of $1.33. OPKO Health has a 1-year low of $0.85 and a 1-year high of $1.75. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -4.23 and a beta of 1.64.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. During the same period last year, the company posted ($0.03) EPS. The company’s revenue was down 31.3% on a year-over-year basis. Equities analysts forecast that OPKO Health will post -0.29 EPS for the current fiscal year.

Insider Buying and Selling

In other OPKO Health news, major shareholder Opko Health, Inc. sold 50,000 shares of OPKO Health stock in a transaction on Monday, July 1st. The shares were sold at an average price of $26.63, for a total value of $1,331,500.00. Following the transaction, the insider now owns 3,508,603 shares in the company, valued at approximately $93,434,097.89. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 736,644 shares of company stock worth $23,874,134. 47.26% of the stock is owned by insiders.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently made changes to their positions in the stock. Rubric Capital Management LP raised its stake in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of OPKO Health by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 5,733,700 shares of the biotechnology company’s stock valued at $8,658,000 after acquiring an additional 183,754 shares during the period. Y.D. More Investments Ltd purchased a new position in shares of OPKO Health in the 2nd quarter valued at $1,840,000. AWM Investment Company Inc. raised its stake in shares of OPKO Health by 18.2% in the 1st quarter. AWM Investment Company Inc. now owns 1,300,000 shares of the biotechnology company’s stock valued at $1,560,000 after acquiring an additional 200,000 shares during the period. Finally, PFG Investments LLC raised its stake in shares of OPKO Health by 2.5% in the 2nd quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock valued at $1,201,000 after acquiring an additional 23,700 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.